• Policy
• Boryung’s Pomalyst generic first to be reimbursed in Korea
• by Lee, Tak-Sun Jan 20, 2025 05:54am

• Policy
• Drug expenditures surge due to the use of high-priced drugs
• by Lee, Tak-Sun Jan 17, 2025 05:53am

• Policy
• Pulmonary fibrosis drug 'Ofev' under consideration for reimb
• by Lee, Tak-Sun Jan 17, 2025 05:53am

• Policy
• Innovative Pharmaceutical Company certification to change
• by Lee, Jeong-Hwan Jan 17, 2025 05:53am

• Policy
• Boryung’s Pomalyst generic soon to be released
• by Lee, Tak-Sun Jan 14, 2025 05:57am

• Policy
• Will 'Lorviqua' secure a deal on drug price negotiations?
• by Lee, Tak-Sun Jan 13, 2025 05:53am

• Policy
• New criteria set for unstable supply and demand drugs
• by Lee, Tak-Sun Jan 13, 2025 05:53am

• Policy
• Chinese pharma targeting KOR, BeiGene gets greenlight
• by Lee, Hye-Kyung Jan 10, 2025 05:52am

• Policy
• AML treatment Mylotarg stalled at the DREC review
• by Lee, Tak-Sun Jan 9, 2025 05:56am

• Policy
• Dong-A ST first to pay the raised new drug approval fee?
• by Lee, Hye-Kyung Jan 7, 2025 06:05am